Ventricular Arrhythmia With Cessation of Infliximab in a Patient With Ankylosing Spondylitis

Özgür Ulaş Özcan

Case Report

Ankilozan Spondilitli Bir Hastada İnfliksimabın Kesilmesiyle Olușan Ventriküler Aritmi

Year 2015, Volume: 68 Issue: 2, 77 - 79, 14.09.2015

Özgür Ulaş Özcan

Abstract

İnfliksimab dirençli ankilozan spondilit (AS) tedavisinde endikasyonu bulunan bir anti-tümör nekroz faktör alfa ajanıdır. İnfliksimabın erken kesilmesi sonucu ventriküler tașikardi gelișen bir hasta sunuyoruz. İnfliksimab tedavisinin tekrar bașlanmasıyla ventriküler tașikardi tekrarlamamıștır. Bu vaka takdimi AS hastalarında inflamasyonun, subklinik ventriküler tutulumun potansiyel olarak ölümcül aritmilere yol açabilmesi nedeniyle, baskılanmasının önemini vurgulamaktadır.

Keywords

Aritmi, Artrit, Senkop, Seronegatif Spondiloartropati, Tümör Nekroz Faktör Alfa

Ethical Statement

Supporting Institution

Thanks

References

1. Papagoras C, Voulgari PV, Drosos AA. Atherosclerosis and cardiovascular disease in the spondyloarthritides, particularly ankylosing spondylitis and psoriatic arthritis. Clin Exp Rheumatol 2013;31:612-20.
2. Roifman I, Beck PL, Anderson TJ et al. Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol 2011;27:174-82.
3. Peters MJ, van der Horst-Bruinsma IE, Dijkmans BA et al. Cardiovascular risk profile of patients with spondylarthropathies, particularly ankylosing spondylitis and psoriatic arthritis. Semin Arthritis Rheum 2004;34:585-92.
4. Kang JH, Chen YH, Lin HC. Comorbidity profiles among patients with ankylosing spondylitis: a nationwide population-based study. Ann Rheum Dis 2010;69:1165-8.
5. Lagrand WK, Visser CA, Hermens WT et al. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 1999;100:96-102.
6. Blangy H, Sadoul N, Dousset B et al. Serum BNP, hs-C-reactive protein, procollagen to assess the risk of ventricular tachycardia in ICD recipients after myocardial infarction. European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology. Europace 2007;9:724-9.
7. Lazzerini PE, Acampa M, Hammoud M et al. Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis. J Rheumatol 2008;35:1958-65.
8. Brunner F, Kunz A, Weber U et al. Ankylosing spondylitis and heart abnormalities: do cardiac conduction disorders, valve regurgitation and diastolic dysfunction occur more often in male patients with diagnosed ankylosing spondylitis for over 15 years than in the normal population? Clin Rheumatol 2006;25:24-9.
9. Knight DM, Trinh H, Le J et al. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 1993;30:1443-53.
10. Maxwell LJ, Zochling J, Boonen A et al. TNF-alpha inhibitors for ankylosingspondylitis. Cochrane Database Syst Rev 2015;4:CD005468.
11. Brewerton DA, Gibson DG, Goddard DH et al. The myocardium in ankylosing spondylitis. A clinical, echocardiographic, and histopathological study. Lancet 1987;1:995-8.
12. Sano K, Watanabe E, Hayano J et al. Central sleep apnoea and inflammation are independently associated wit arrhythmia in patients with heart failure. Eur J Heart Fail 2013;15:1003-10.
13. Tam LS, Kitas GD, Gonzalez-Gay MA. Can suppression of inflammation by anti- TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis? Rheumatology 2014;53:1108-19.
14. Senel S, Cobankara V, Taskoylu O et al. Effect of infliximab treatment on QT intervals in patients with ankylosing spondylitis. J Investig Med 2011;59:1273- 5.